Biochemical, physiologic, and clinical effects of L-methylfolate in schizophrenia: A randomized controlled trial

Abstract

Folic acid supplementation confers modest benefit in schizophrenia, but its effectiveness is influenced by common genetic variants in the folate pathway that hinder conversion to its active form. We examined physiologic and clinical effects of L-methylfolate, the fully reduced and bioactive form of folate, in schizophrenia. In this randomized, double-blind trial, outpatients with schizophrenia (n=55) received L-methylfolate 15 mg or placebo for 12 weeks. Patients were maintained on stable doses of antipsychotic medications. The pre-defined primary outcome was change in plasma methylfolate at 12 weeks. Secondary outcomes included change in symptoms (PANSS, SANS, CDSS), cognition (MATRICS composite) and three complementary MRI measures (working memory-related activation, resting connectivity, cortical thickness). Primary, mixed model, intent-to-treat analyses covaried for six genetic variants in the folate pathway previously associated with symptom severity and/or response to folate supplementation. Analyses were repeated without covariates to evaluate dependence on genotype. Compared to placebo, L-methylfolate increased plasma methylfolate levels (d=1.00, p=.0009) and improved PANSS Total (d=.61, p=.03) as well as PANSS Negative and General Psychopathology subscales. While PANSS Total and General Psychopathology changes were influenced by genotype, significant PANSS Negative changes occurred regardless of genotype. No treatment differences were seen in other symptom rating scales or cognitive composite scores. Patients receiving L-methylfolate exhibited convergent changes in ventromedial prefrontal physiology, including increased task-induced deactivation, altered limbic connectivity, and increased cortical thickness. In conclusion, L-methylfolate supplementation was associated with salutary physiologic changes and selective symptomatic improvement in this study of schizophrenia patients, warranting larger clinical trials.

Introduction

Evidence from clinical, genetic, and brain imaging studies has implicated altered folic acid metabolism in schizophrenia. Patients with schizophrenia frequently exhibit reduced blood folate levels (1, 2), which have in turn associated with more severe negative symptoms (3). This relationship is especially pronounced in patients who carry low-functioning genetic variants, such as MTHFR 677C>T, in the folate pathway (4, 5). The MTHFR 677T variant has also been associated with altered activation in prefrontal networks during executive function tasks (6, 7).

Folic acid supplementation has been proposed as an adjunctive treatment for schizophrenia, with the idea that correcting underlying metabolic deficiencies could improve clinical outcomes. Three previous randomized, placebo-controlled clinical trials of folic acid supplements have suggested efficacy, although results have been modest and difficult to generalize. An initial cross-over study of schizophrenia patients treated with a multivitamin that included folic acid indicated improvement in Positive and Negative Syndrome Scale (PANSS) total score, although enrollment was limited to patients with elevated baseline homocysteine levels (8). Two subsequent studies of folic acid with or without vitamin B12 indicated small but significant effects on negative symptoms, but the effects were limited to patients who carried certain genetic variants such as MTHFR 677T (9, 10).

Conversion of folic acid to its fully active form, L-methylfolate, requires the action of MTHFR and other enzymes in the folate pathway (Figure S1). The efficacy of folic acid may be reduced for individuals who carry low-functioning variants in these enzymes, which have been associated with altered blood folate levels both at baseline and following folic acid treatment (10, 11). Conversely, L-methylfolate bypasses several of these enzymes. Compared to folic acid, L-methylfolate may reduce variation in the physiologic and clinical responses to supplementation that would otherwise occur due to the presence of low-functioning genetic variants in certain individuals.

The present study, a randomized, double-blind, parallel arm, placebo-controlled clinical trial, evaluated biochemical, physiologic, and clinical effects of 12 weeks of 15 mg oral L-methylfolate supplementation in medicated outpatients with schizophrenia. The primary endpoint was change in blood methylfolate level; secondary endpoints included change in symptoms, cognition, and structural and functional MRI indices relevant to schizophrenia. We also explored the dependence of outcomes on common, functional genetic variants in six folate-related enzymes, each of which had been associated with variation in negative symptoms and/or response to folate supplementation in other work published during the course of the trial (4, 10, 12).

Methods and Materials

Study Design

This was a single-site, randomized, double-blind, placebo-controlled, parallel-group, 12-week trial of supplementation with L-methylfolate conducted at an urban community mental health clinic in Boston from May 2009 to May 2014. The double-blind portion of the trial was immediately followed by an open-label 12-week extension where all participants received L-methylfolate, primarily to assess safety outcomes. Following a screening visit, eligible participants completed a two-week single-blind placebo lead-in phase, after which clinical inclusion criteria were re-assessed (baseline visit). Study procedures were approved by the Partners HealthCare Human Research Committee. Enrollment continued until the pre-specified endpoint was reached (50 Week 12 completers).

Participants

Eligible participants had a diagnosis of schizophrenia, as confirmed with the Structured Clinical Interview for DSM-IV-TR, and provided written informed consent. Please refer to Supplementary Methods for inclusion and exclusion criteria and randomization procedures.

Study Visits

Subjects returned to the clinic for follow-up visits at Weeks 2, 4, 6, 8, 10, 12, and 24 following the Baseline visit. Medication was dispensed and interval adverse events were recorded at each visit. Blood for plasma methylfolate, homocysteine, methionine, and B12 levels was drawn at Baseline and Weeks 2, 8, 12, and 24. Clinical measurements, including the PANSS, Scale for Assessment of Negative Symptoms (SANS), and Calgary Depression Scale for Schizophrenia (CDSS) were collected at Baseline and Weeks 2, 8, 12, and 24. Subjects also completed the MATRICS (Measurement and Treatment Research to Improve Cognition in Schizophrenia) battery at Baseline and at Weeks 6, 12, and 24. Blood was collected for genotyping at the baseline visit.

MRI

Additional details of MRI acquisition, stimulus presentation, and pre-processing methods are described in Supplementary Methods. Briefly, eligible patients underwent MRI scans at 3T (Siemens TIM Trio with a 12 channel quadrature head coil) within a two-week window before the baseline visit and again within two weeks after the Week 12 visit. Pre- and post-treatment scans were identical except for specific working memory stimuli.

A high resolution T1 image was obtained to measure cortical thickness and for co-registration of functional scans. Resting state functional MRI (fMRI) data were acquired during a standard six minute sequence (13). Patients were instructed to keep their eyes open and lay as still as possible.

Task-based fMRI was conducted during performance of a version of the Sternberg Item Recognition Paradigm (SIRP), which evaluated working memory function at four different loads (1, 3, 5, or 7 consonants; Figure S2). Stimuli were presented with Eprime 1.1 software. The SIRP has been associated with linear increases in task-positive (e.g., frontoparietal) network activation, and in task-negative (e.g., limbic/default) network deactivation as a function of working memory load (14–16), and with minimal learning effects (17). Prior to scanning, subjects performed a practice run to ensure they understood the task.

Genotype and Blood Chemistry

DNA extracted from whole blood samples was genotyped (Sequenom MassARRAY) for six variants within folate-related genes: MTHFR (rs1801133), MTR (rs1805087), FOLH1 (rs202676), COMT (rs4680), DHFR (rs2618372), and GCH1 (rs8007267). These variants were selected because they previously associated with symptom severity in schizophrenia (4, 5), with response to folic acid supplementation in schizophrenia (9, 10), or with response to L-methylfolate supplementation in depression (12). Figure S2 depicts the location of each marker within the folate pathway.

Liquid chromatography with tandem mass spectroscopy measured plasma methylfolate (18), homocysteine (19), and methionine (20). Plasma vitamin B12 levels were measured using the SimulTRAC-SNB radioassay kit (MP Diagnostics, Orangeburg, NY).

Outcomes

Primary analysis focused on the double-blind part of the trial. A biochemical measure, change in plasma methylfolate, was the pre-defined primary endpoint in this first dedicated study of L-methylfolate in schizophrenia patients. Genetic alteration of enzymes situated both upstream and downstream of where methylfolate enters into the one carbon cycle have been implicated in schizophrenia (4). This, coupled with the well-known problem of treatment non-adherence in schizophrenia, could complicate examination of other clinical or physiologic endpoints without documented changes in plasma levels. Secondary endpoints included changes in clinical measures that had previously been responsive to folic acid (SANS, excluding the Attention Subscale and Inappropriate Affect item (21); PANSS), a single global measure of cognitive change (MATRICS composite score), and changes in plasma homocysteine, methionine, and vitamin B12 levels. Change in depression score (CDSS) was included to rule out confounding effects of improved mood on other clinical outcomes, given the previously reported improvement in depression with 15 mg L-methylfolate (22). Finally, we included three complementary MRI measures – working memory-related activation, cortical thickness, and ventromedial prefrontal cortex (vmPFC) connectivity – that have consistently been found to differ between schizophrenia patients and healthy individuals (14, 15, 23, 24), to determine whether L-methylfolate restored more normal brain physiology and structure.

Statistical Analysis

The target sample size of 50 completers provided power of 80% to detect an effect size of 0.8 between groups with alpha (two-tailed) set at 0.05 and allowing for a 10% drop-out rate. Within- and between-group differences for change in blood chemistry and clinical measures were assessed using linear mixed model analysis with unstructured variance-covariance structure (SAS v9.2) that included all randomized participants (intent-to-treat) and was centered at week 12. The dependent variable was difference from baseline, and baseline values and week of measurement were included as covariates. To test for the dependence of main effects on genotype, parallel analyses were conducted with and without the simultaneous entry of genotypes into the model as covariates, with two levels per genotype (homozygous for the major allele versus heterozygous + homozygous for the minor allele). Variables that demonstrated significant differences between treatment groups were subject to additional analyses that included covariates for any demographic or clinical variables that differed significantly at baseline between treatment groups. Exploratory analyses evaluated specific genotype × treatment interactions among measures showing significant treatment effects.

Additional details of MRI statistical analysis are described in the Supplementary Methods section. Briefly, for the task-based fMRI analysis, we focused on recall (probe presentation and response) time points and used a general linear model to determine at each voxel the extent to which linear activation was observed as load was parametrically increased from one to seven items (25). Parameter estimates and residual errors were computed for each subject, at each time point, and then subtracted to create a difference map for each subject. Difference maps were entered into a random-effects group analysis to determine whether treatment-related changes differed between treatment groups. The same general approach was used to evaluate treatment-related changes in cortical thickness: first-level analysis created subtraction maps for each subject, and second-level analysis contrasted cortical thickness changes between treatment groups. To correct for multiple comparisons, 10,000 Monte Carlo simulations of synthesized white Gaussian noise were conducted across the brain volume (for task-based fMRI) or surface (for cortical thickness) to determine whether clusters of a certain size at a certain threshold (p<.05) would be found by chance (cluster-wise probability). These methods set the corrected overall probability level to 0.05 (two-tailed).

For resting-state connectivity, we examined correlation in blood oxygen level dependent signal time course between seed regions in the left and right ventromedial prefrontal cortex (vmPFC) and the orbitofrontal cortex (OFC). The vmPFC seeds, 6 mm spheres (centered at MNI coordinates x=−7, y=32, z=−13 and x=5, y=22, z=−8), were generated in a previous study (25) of 40 schizophrenia patients (24 overlapping with baseline scans in the current sample) and 40 demographically matched control subjects based on the maximal difference between patients and controls on SIRP-induced deactivation during correct performance; in that analysis, patients demonstrated abnormally increased connectivity between both vmPFC seeds and lateral OFC (lOFC). Here, using the same within-subject approach described above, we determined whether pre- to post-treatment vmPFC to OFC connectivity changes differed between treatment groups. Correction for multiple comparisons within the OFC was implemented using AlphaSim software, setting the corrected clusterwise alpha at 0.05.

Post hoc analyses of relationships among significant clinical, biochemical, and imaging findings were corrected using the false discovery rate (Supplementary Methods).

Results

Patients

Between May 2009 and September 2013, 78 patients were screened, 61 were eligible, and 55 were randomized to L-methylfolate (n=29) or placebo (n=26). Enrollment continued until 50 subjects completed the week 12 assessment. Five subjects discontinued the study before week 12; of these, four were lost to follow-up and one was terminated due to hospitalization for increased psychosis (91% completion rate; Figure S3). 44 subjects completed the 12-week open-label extension. Treatment groups did not differ at baseline for any clinical, cognitive, biochemical, or genotype measure (Table 1), excepting anticonvulsant use, which was more common in the L-methylfolate group. Genotypes were in Hardy Weinberg equilibrium, with the exception of GCH1 (χ²=4.00, p=.045), which reflected previously described differences in allele frequency between racial groups (http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=8007267).

Table 1.

Baseline demographic, clinical, biochemical, and genotype measures

Measure	L-Methylfolate	Placebo	Statistics	p-value
DEMOGRAPHICS
Age, years	46.3 (9.2)	44.7 (12.9)	t=0.54	n.s.
Male, %	82.8	73.1	χ2=0.75	n.s.
Caucasian, %	58.6	69.2	χ2=0.67	n.s.
Duration of illness, years	19.4 (10.3)	21.4 (12.3)	t=0.63	n.s.
Schooling, years	13.2 (2.3)	12.2 (1.7)	t=1.96	n.s.
Current smoker, %	48.3	38.5	χ2=0.54	n.s.
MEDICATION USE
Typical antipsychotics, %	31.0	15.4	χ2=1.86	n.s.
Atypical antipsychotics, %	79.3	96.2	χ2=3.50	n.s.
Antidepressants, %	41.4	46.2	χ2=0.13	n.s.
Anticonvulsants, %	44.8	15.4	χ2=5.66	p=0.02
SYMPTOMS/COGNITION
PANSS total	74.5 (12.6)	79.7 (15.9)	t=1.36	n.s.
PANSS positive	18.0 (5.1)	19.7 (6.0)	t=1.13	n.s.
PANSS negative	20.8 (5.4)	22.3 (4.4)	t=1.10	n.s.
PANSS general	35.6 (6.1)	37.7 (8.5)	t=1.05	n.s.
SANS total	32.7 (15.0)	36.3 (10.1)	t=1.03	n.s.
CDSS total	3.0 (2.4)	2.3 (2.6)	t=1.02	n.s.
MATRICS composite total	30.6 (15.6)	26.7 (14.9)	t=0.94	n.s.
BLOOD CHEMISTRIES
Plasma methylfolate, nmol/L	40.7 (28.1)	46.1 (29.4)	t=0.69	n.s.
Plasma homocysteine, μmol/L	17.8 (6.5)	17.2 (5.4)	t=0.36	n.s.
Plasma methionine, μmol/L	31.6 (15.5)	28.5 (12.9)	t=0.79	n.s.
Plasma B12, pmol/L	543 (279)	448 (215)	t=1.39	n.s.
GENOTYPES
MTHFR rs1801133 CC/T-carrier, %	46.4/53.6	46.2/53.8	χ2=0.00	n.s.
MTR rs1805087 AA/G-carrier, %	67.9/32.1	53.8/46.2	χ2=1.11	n.s.
FOLH1 rs202676 TT/C-carrier, %	42.9/57.1	57.7/42.3	χ2=1.19	n.s.
COMT rs4680 GG/A-carrier, %	32.1/67.9	23.1/76.9	χ2=0.55	n.s.
DHFR rs2618372 CC/A-carrier, %	63.0/37.0	56.0/44.0	χ2=0.26	n.s.
GCH1 rs8007267 CC/T-carrier, %	48.1/51.9	56.0/44.0	χ2=0.32	n.s.

Values given as mean (standard deviation) unless otherwise noted. PANSS=Positive and Negative Syndrome Scale, SANS=Scale for Assessment of Negative Symptoms, CDSS=Calgary Depression Scale for Schizophrenia, MATRICS=Measurement and Treatment Research to Improve Cognition in Schizophrenia Consensus Cognitive Battery.

Biochemistry

When including genotypes (Table 2), plasma methylfolate levels increased significantly in the L-methylfolate group (mean change=450 nmol/L, 95% C.I.=265 to 635, p<.0001) but not the placebo group, yielding a significant between-group difference (mean difference=446 nmol/L, 95% C.I.=197 to 695, p=.0009, Cohen’s d=1.00; see Table 2). Plasma homocysteine levels fell within the L-methylfolate group but the decrease was not significantly different than the change in the placebo group. Plasma methionine levels decreased slightly in both groups but changes did not reach significance. Plasma B12 levels did not change in either group. Inclusion of anticonvulsant use as a covariate did not affect within- and between-group changes in plasma methylfolate levels, which remained significant (Table S1). Changes in biochemistry were not substantially different when genotypes were removed from the model (Table 3).

Table 2.

Change from Baseline to Week 12 for biochemical, clinical, and cognitive measures, adjusted for genotypes

Measure	df	L-Methylfolate	Placebo	Difference
BLOOD CHEMISTRIES
Plasma methylfolate, nmol/L	36	450 (265 to 635), p<.0001	5 (−163 to 172), p=.96	446 (197 to 695), p=.0009
Plasma homocysteine, μmol/L	36	−3.9 (−7.4 to −0.4), p=.03	−0.9 (−4.1 to 2.2), p=.55	−3.0 (−7.6 to 1.7), p=.21
Plasma methionine, μmol/L	36	−4.3 (−12.6 to 4.0), p=.91	−4.1 (−9.5 to 1.4), p=.31	−0.2 (−10.6 to 9.6), p=.92
Plasma B12, pmol/L	36	−57 (−139 to 25), p=.17	−2 (−78 to 75), p=.97	−55 (−167 to 56), p=.32
SYMPTOMS/COGNITION
PANSS total	37	−7.0 (−11.1 to −3.0), p=.001	−0.9 (−4.5 to 2.7), p=.62	−6.1 (−11.6 to −0.6), p=.03
PANSS positive	37	−1.5 (−3.3 to 0.3), p=.10	−1.3 (−2.9 to 0.4), p=.13	−0.2 (−2.8 to 2.3), p=.84
PANSS negative	37	−1.9 (−3.7 to −0.1), p=.04	1.1 (−0.6 to 2.8), p=.19	−3.0 (−5.4 to −0.5), p=.02
PANSS general	37	−4.5 (−6.6 to −2.3), p=.0001	−0.1 (−2.1 to 1.8), p=.88	−4.3 (−7.2 to −1.4), p=.004
SANS total	37	1.5 (−2.6 to 5.6), p=.46	2.2 (−1.6 to 6.0), p=.25	−0.7 (−6.3 to 4.9), p=.80
CDSS total	37	0.3 (−1.1 to 1.6), p=.68	−0.4 (−1.6 to 0.8), p=.49	0.7 (−1.1 to 2.5), p=.44
MATRICS composite total	34	1.2 (−1.5 to 4.0), p=.37	0.2 (−2.4 to 2.8), p=.90	1.1 (−2.7 to 4.9), p=.57

Values given as mean (95% confidence interval). df=degrees of freedom, PANSS=Positive and Negative Syndrome Scale, SANS=Scale for Assessment of Negative Symptoms, CDSS=Calgary Depression Scale for Schizophrenia, MATRICS=Measurement and Treatment Research to Improve Cognition in Schizophrenia Consensus Cognitive Battery.

Table 3.

Change from Baseline to Week 12 for biochemical, clinical, and cognitive measures, not adjusted for genotypes

Measure	df	L-Methylfolate	Placebo	Difference
BLOOD CHEMISTRIES
Plasma methylfolate, nmol/L	51	582 (400 to 765), p<.0001	−1 (−183 to 181), p=.99	583 (326 to 841), p<.0001
Plasma homocysteine, μmol/L	51	−2.8 (−5.5 to −0.2), p=.03	0.6 (−2.0 to 3.2), p=.64	−3.5 (−7.2 to 0.2), p=.07
Plasma methionine, μmol/L	51	−3.4 (−10.7 to 4.0), p=.36	−4.0 (−10.0 to 2.0), p=.16	0.6 (−8.6 to 9.9), p=.89
Plasma B12, pmol/L	51	−26 (−86 to 34), p=.38	8 (−53 to 69), p=.79	−34 (−120 to 52), p=.43
SYMPTOMS/COGNITION
PANSS total	52	−4.7 (−8.2 to −1.3), p=.008	−1.5 (−5.0 to 1.9), p=.38	−3.2 (−8.1 to 1.7), p=.19
PANSS positive	52	−1.2 (−2.4 to 0.1), p=.07	−1.5 (−2.8 to −0.2), p=.02	0.3 (−1.5 to 2.1), p=.71
PANSS negative	52	−1.3 (−2.6 to 0.0), p=.05	0.9 (−0.4 to 2.2), p=.19	−2.1 (−4.0 to −0.3), p=.02
PANSS general	52	−2.5 (−4.7 to −0.4), p=.02	−0.6 (−2.8 to 1.6), p=.60	−2.0 (−5.1 to 1.1), p=.21
SANS total	52	−0.5 (−3.5 to 2.5), p=.73	2.4 (−0.6 to 5.4), p=.11	−2.9 (−7.1 to 1.3), p=.17
CDSS total	52	−0.0 (−1.0 to 0.9), p=.95	−0.7 (−1.7 to 0.2), p=.12	0.7 (−0.6 to 2.0), p=.29
MATRICS composite total	48	1.1 (−1.0 to 3.1), p=.31	−0.4 (−2.6 to 1.8), p=.70	1.5 (−1.5 to 4.5), p=.33

Values given as mean (95% confidence interval). df=degrees of freedom, PANSS=Positive and Negative Syndrome Scale, SANS=Scale for Assessment of Negative Symptoms, CDSS=Calgary Depression Scale for Schizophrenia, MATRICS=Measurement and Treatment Research to Improve Cognition in Schizophrenia Consensus Cognitive Battery.

Changes in Symptoms and Cognition

When including genotype covariates (Table 2), PANSS total score declined significantly in the L-methylfolate group compared to baseline (mean change=−7.0 points, 95% C.I. −11.1 to −3.0, p=.001) and changed significantly more than in the placebo group (mean difference=−6.1 points, 95% C.I. −11.6 to −0.6, p=.03, Cohen’s d=0.63). Statistically significant improvement was also evident for the PANSS negative (d=0.68) and general psychopathology (d=0.84) subscales (Table 2). Significant between-group differences persisted when including anticonvulsant use as a covariate (Table S1). No significant within- or between-group changes were observed for PANSS positive, SANS, CDRS, or MATRICS composite scores (Table 2). When genotype covariates were excluded, change in methylfolate and PANSS negative continued to differ between treatment groups, but between-group differences for changes in PANSS total and general psychopathology became non-significant (Table 3).

Interactions of Significant Variables with Genotype

For plasma methylfolate and PANSS negative, no significant treatment × genotype interactions were observed, suggesting that treatment effects occurred independent of genotype. For PANSS total and general psychopathology, significant treatment × genotype interactions were observed only for the MTR 2756A>G variant, where improvement was seen only among patients who received L-methylfolate and who were homozygous for the 2756G allele (Table S2).

Changes in MRI Measures

A total of 35 patients (20 L-methylfolate, 1/20 left-handed; and 15 placebo, 2/15 left-handed) had usable pre- and post-treatment scans for structural and resting-state MRI analyses. Of these, 25 patients (13 L-methylfolate, 0/13 left-handed; and 12 placebo, 0/12 left-handed) met criteria for inclusion in the task-based MRI analysis based on above-chance performance and minimal head motion. Head motion did not differ between groups (Table S3).

Performance on the working memory task did not differ between groups at baseline, and did not change significantly over time in either group (Table S4). Omnibus voxel-wise comparison of pre- and post-treatment scans in the L-methylfolate and placebo groups indicated a single, large cluster encompassing bilateral medial orbitofrontal cortex (mOFC), lateral orbitofrontal cortex (lOFC), and nucleus accumbens, with a significant time × treatment interaction following whole-brain correction for multiple comparisons (Table S5). The mOFC normally deactivates during working memory tasks, although blunted deactivation is observed in patients with schizophrenia and unaffected siblings (26). Here, patients receiving L-methylfolate exhibited potentiated deactivation following treatment, while the reverse pattern was evident in patients receiving placebo (Figure 1a).

Figure 1.

Time × treatment effects on MRI measures. Bar graphs indicate mean and standard error for extracted values within significant clusters. LMF=L-methylfolate, PBO=placebo. (a) Working memory load-dependent activation/deactivation during the Sternberg Item Recognition Paradigm. Visualized cluster survived whole-volume correction for multiple comparisons. (b) Cortical thickness. Visualized cluster survived surface-wide correction for multiple comparisons. (c) Functional connectivity between a seed region in the left ventromedial prefrontal cortex (vmPFC) and the entire orbitofrontal cortex (OFC). Visualized cluster survived small-volume correction within the OFC.

Omnibus vertex-wise comparison of structural MRI scans indicated two clusters with significant time × treatment interactive effects on cortical thickness, following surface-wide correction for multiple comparisons (Table S6). The larger cluster encompassed the left medial prefrontal cortex, with the largest effect seen in the mOFC, reflecting pre- to post-treatment cortical thickness increases in the L-methylfolate group but not the placebo group (Figure 1b). The smaller cluster, located in the right interior and middle temporal gyri, was characterized by the inverse pattern.

Finally, a focused functional connectivity analysis of resting-state MRI scans was then performed, examining connectivity between seed regions in the left and right vmPFC and the entire orbitofrontal cortex. Pre-to post-treatment connectivity differed between groups between the left vmPFC and a single cluster within the right lOFC; patients receiving L-methylfolate exhibited a pre-to-post treatment reduction in connectivity between these limbic regions that was not evident among patients receiving placebo (Figure 1c, Table S7). A similar pattern was observed using the right vmPFC seed, which demonstrated treatment-related reduction in connectivity to right lOFC at trend level. A third cluster, reflecting left vmPFC connectivity to left lOFC, displayed the inverse pattern. Exploratory whole-brain analyses found no additional clusters that reached significance.

All significant imaging findings persisted when analyses were adjusted for genotype (Table S8).

Adverse Events

Treatment-emergent adverse events were mild and did not differ significantly between the L-methylfolate and placebo groups (Table S9). One subject in each treatment group was hospitalized for worsening symptoms during the double-blind phase.

Supplementary Data

Please refer to Supplementary Methods, Results and Tables S10–S14 for post hoc analyses of negative symptom variance; post hoc analyses relating significant clinical and imaging changes to each other as well as to methylfolate levels; and results from the 12-week open-label extension.

Discussion

Supplementation with 15 mg daily L-methylfolate was associated with improvements in several key biochemical, clinical, and brain imaging measures in this randomized clinical trial. In the setting of significant increases in blood methylfolate levels, patients who received L-methylfolate exhibited reductions in PANSS total, general psychopathology, and negative scores that were of moderate-to-large effect size, although modest in absolute change. Patients in the L-methylfolate group also exhibited convergent changes in medial prefrontal structure and function that suggest a partial normalization of limbic dysfunction.

In the only previous randomized trial of methylfolate in schizophrenia, Godfrey and colleagues (27) reported a significant decrease on a 4-point scale of global clinical outcome in patients who received 15 mg daily methylfolate for 6 months. That smaller study involved 17 patients, each of whom had substantial deficits in red blood cell folate (<200 μg/L) at the time of randomization. The same trial also included 24 patients with depression, who also demonstrated significant improvement on the same global scale. A more recent placebo-controlled study of L-methylfolate augmentation of SSRIs in depression indicated a significant benefit (response rate, change in depression score) at a dose of 15 mg after 30 days (22).

To minimize the possibility that changes in schizophrenia symptoms might reflect improvement in depression, the present study excluded patients with active depression, and changes in depression score were monitored with the CDSS. There were no significant differences between treatment groups on change in CDSS scores, suggesting that the observed improvements in PANSS scores did not reflect L-methylfolate related improvement in depression.

Several differences emerge when contrasting the present results to previous studies of folic acid supplementation in schizophrenia. Both Hill et al. (9) and Roffman et al. (10) reported improvement in negative symptoms, as measured with the SANS, after 12 or 16 weeks of treatment with 2 mg folic acid; however, in the Hill et al. study, improvement occurred only in patients who carried the MTHFR 677T allele, and in the Roffman et al. study, SANS improvement was only significant after including MTHFR and other genotypes into the model. Here, L-methylfolate was associated with significant improvement in PANSS negative score regardless of genotype, although significant differences were not seen for the SANS. While PANSS negative and SANS scores correlated strongly, and both scales saw greater improvement in expressive (rather than social amotivation) symptoms, significantly greater variance in SANS ratings may have hampered detection of treatment effects in this relatively small sample.

Further, as in Levine and colleagues’ (8) study of vitamin supplementation in schizophrenia (which included 2 mg folic acid, but studied only patients with elevated homocysteine), PANSS total scores improved significantly, albeit modestly, following active treatment. Here, though, improvement in both PANSS total and PANSS general psychopathology scores were dependent on genotype, and specifically on a non-synonymous variant in MTR that has been previously associated with altered homocysteine metabolism (28). MTR, which generates one-carbon moieties through the remethylation of homocysteine to methionine, is situated immediately downstream of where L-methylfolate enters into the folate metabolic pathway (Figure S2). It remains unclear why changes in these specific PANSS measures, and not in PANSS negative, should be dependent on MTR genotype, although notably the same variant also influenced response to L-methylfolate in depression, and in the same direction (more improvement in G-allele carriers) (12). It is also notable that genetic variants that occur upstream of where L-methylfolate enters into the folate pathway (e.g., FOLH1, MTHFR) did not influence treatment response for any measure showing a significant between-group difference. This pattern suggests that functional genetic variants in these enzymes may not affect treatment response to L-methylfolate in the way that they do for folic acid, which enters into the pathway further upstream (9, 10). That said, the lack of significant treatment effects on homocysteine or methionine suggests that metabolic dysfunction downstream of where methylfolate enters into the one carbon cycle – potentially due to variants that were not included in the model – may ultimately influence efficacy of L-methylfolate in some patients.

The present study also included pre- and post-treatment MRI measures to provide structural and functional brain correlates of treatment response. Altered activation of the dorsolateral prefrontal cortex (dlPFC) and other regions within the frontoparietal control network (FPCN) during working memory performance and other executive function tasks have been well documented in schizophrenia, and have also been related to MTHFR 677C>T genotype (6, 7). More recently, impaired deactivation of task-negative regions, such as the medial prefrontal cortex (mPFC) has also been described in schizophrenia (16, 26, 29). A recent study of 40 schizophrenia patients and 40 demographically matched controls conducted by our group indicated that while altered FPCN activation in schizophrenia may largely reflect between-group differences in task performance, impaired deactivation of vmPFC (including mOFC) appears to be a trait difference that distinguishes patients from controls regardless of task performance (25). The same study found differences in resting-state connectivity within the vmPFC, characterized by increased connectivity to lOFC in patients. This pattern was consistent with other recent work demonstrating hyperconnectivity of limbic regions in schizophrenia (30, 31).

Following treatment, patients who received L-methylfolate demonstrated a significantly greater potentiation of medial and lateral OFC deactivation during working memory compared to those who received placebo. This was the only significant finding to emerge from our whole-brain fMRI analysis following correction for multiple comparisons. L-methylfolate was also associated with changes in resting-state connectivity between vmPFC and lOFC that were mostly consistent with dampened limbic hyperconnectivity. Finally, L-methylfolate was also associated with an increase in cortical thickness throughout the mPFC. Collectively, these findings suggest a partial restoration of mPFC structure and function following L-methylfolate treatment. Lack of improvement on MATRICS or working memory indices may suggest a dissociation of MRI and cognitive results. Alternatively, MRI changes may be a more sensitive measure of treatment-induced neuroplasticity; if so, cognitive improvement occurring downstream of neuroplastic changes may be detectable in a larger sample. Structural and functional changes also did not correlate with symptom change, although again this relatively small sample was potentially underpowered to observe such a relationship.

Similarly, changes in blood methylfolate level did not correlate with changes in clinical and brain imaging measures that differed significantly between treatment groups. While this pattern could also reflect insufficient power, an alternative possibility is that blood and central nervous system (CNS) methylfolate levels do not correlate, especially at higher concentrations. This pattern has been demonstrated for unmethylated folate, where CNS levels plateau due to tight regulation by transporters at the blood brain barrier (32). Here, clinical and MRI changes may have reflected rise in methylfolate up to, but not beyond, CNS saturation.

While the results of this study are promising with regard to the use of supplemental L-methylfolate in schizophrenia, several limitations should be acknowledged. With a single site, it is unclear whether the present results would generalize to a larger population. Statistically significant clinical improvements were still modest, although relatively small rating changes have been described as clinically meaningful in other samples with moderately severe baseline symptoms (33, 34). The small sample increases the risk for Type II error, particularly in regard to specific genotype interaction results, which should be regarded as exploratory. With regard to Type I error, we did not include a formal correction for multiple comparisons across secondary clinical outcome measures, although several outcomes of interest (SANS, PANSS) were not independent, and another (CDSS) was included to rule out confounding effects of improvement in depression. Treatment groups differed in use of anticonvulsants, which can affect folate metabolism (35, 36), although significant clinical effects persisted after adjustment for anticonvulsant status. Finally, between-group differences could potentially reflect differences in dietary folate intake, which was not measured due to the poor reliability of nutritional questionnaires for B vitamins (37); however, that the groups maintained comparable blood levels of vitamin B12, which is frequently found in the same fortified food products as folic acid (38, 39), argues against this concern.

Although replication in larger samples will be necessary to address these limitations, the present results demonstrate potential for L-methylfolate supplementation to improve both clinical and neurophysiologic outcomes in schizophrenia. Further, they suggest that L-methylfolate-related improvement in negative symptoms, a particularly disabling syndrome in schizophrenia, may be less dependent on common genetic variants in the folate pathway compared to other folate-based interventions.